Phase 3Completed

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Sponsor
Restorbio Inc. (Industry)
Enrollment
1,024 enrolled
Conditions
Respiratory Tract Infections
Interventions
Dactolisib; Placebo
Ages
older adults
Registry
NCT04668352

Full record on ClinicalTrials.gov

From the registry

To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.

Primary outcomes

  • Percentage of Subjects With Clinically Symptomatic Respiratory Illness

History

  1. Results first posted

  2. Last registry update

  3. Registered

  4. Primary completion

  5. Started